ERNAW · Ernexa Therapeutics Inc.
$0.03
0.00 (-1.54%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$3.25M
Shares
1.63M
Volume · Oct 27
1912
Avg daily vol (3M)
25.96K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
Available close range$0.02–0.08
Avg vol 30d27K
Last earningsAug 7, 2020
DataJul 2026–Oct 2026
Filing10-Q · Aug 6
The closing range uses available history since Jul 29, 2026; less than a full year is stored.
Latest filings
8-K
Regulation FD disclosure
·
filed Oct 15, 2026
Ernexa Therapeutics Inc. made an investor presentation available on October 15, 2026, including forward-looking statements, and planned same-day distribution through its website.
Read the 8-K
10-Q
filed Aug 6, 2026
Read the 10-Q
Technicals
trend & momentum for long-term holders illustrative — not investment adviceMarket signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
4 of 17 funds reported for Sep 30 · net +4.2K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
No short-interest data
Volume signal
Normal
Volume near normal
Institution breadth
Steady
17 holders — mid 3-yr range
Price context
position in its available closing range
Range low $0
Now $0 · 7%
Range high $0
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERNAW
this stock
Ernexa Therapeutics Inc.
|
$3.25M | — | +755.9% | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.20B | +14.9% | +46.2% | 30.2 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +5.7% | +20.8% | 20.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +605.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
16
- % held
- 176.2%
- Reported
- 4 of 17
- Top holder
- Bleichroeder LP
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERNAW | +18.6% | -19.1% | — | -19.6% | — |
| SPY | +0.1% | +0.7% | +4.9% | +0.9% | +12.9% |
| vs SPY | +18.5% | -19.8% | — | -20.5% | — |